Protein Summary
Mediates effects on cell migration and adhesion through its different partners. During development plays a role in blood and lymphatic vessels separation by binding CLEC1B, triggering CLEC1B activation in platelets and leading to platelet activation and/or aggregation (PubMed:14522983, PubMed:15231832, PubMed:17616532, PubMed:18215137, PubMed:17222411). Interaction with CD9, on the contrary, attenuates platelet aggregation induced by PDPN (PubMed:18541721). Through MSN or EZR interaction promotes epithelial-mesenchymal transition (EMT) leading to ERZ phosphorylation and triggering RHOA activation leading to cell migration increase and invasiveness (PubMed:17046996, PubMed:21376833). Interaction with CD44 promotes directional cell migration in epithelial and tumor cells (PubMed:20962267). In lymph nodes (LNs), controls fibroblastic reticular cells (FRCs) adhesion to the extracellular matrix (ECM) and contraction of the actomyosin by maintaining ERM proteins (EZR; MSN and RDX) and MYL9 a ...more
- ENST00000294489
- ENSP00000294489
- ENSG00000162493
- ENST00000376057
- ENSP00000365225
- ENST00000376061
- ENSP00000365229
- ENST00000475043
- ENSP00000426063
- ENST00000487038
- ENSP00000427537
- ENST00000513143
- ENSP00000425304
- ENST00000617617
- ENSP00000479591
- ENST00000621990
- ENSP00000478125
- GP36
- T1A
- GP36
- GP40
- Gp38
- OTS8
- T1A2
- TI1A
- T1A-2
- AGGRUS
- HT1A-1
- PA2.26
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
PubMedID | 0.96 | ||
biological term | 0.92 | ||
kinase perturbation | 0.91 | ||
biological process | 0.82 | ||
gene perturbation | 0.8 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 4914.16 (req: < 5)
Gene RIFs: 235 (req: <= 3)
Antibodies: 1133 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 4914.16 (req: >= 5)
Gene RIFs: 235 (req: > 3)
Antibodies: 1133 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 27
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0